What is Fibrosing Mediastinitis

TL;DR: Fibrosing mediastinitis is a rare, serious condition characterized by the overgrowth of dense, fibrous tissue in the mediastinum—the central compartment of the chest—which can constrict vital structures like major blood vessels and airways. It is most frequently caused by an abnormal immune response to past infections, such as histoplasmosis, leading to progressive scarring that requires specialized medical management.

What is Fibrosing Mediastinitis and how does it affect the body?

Fibrosing mediastinitis is a disorder where the body produces excessive, inflammatory scar tissue within the mediastinum, the area between the lungs that houses the heart, esophagus, trachea, and major blood vessels. Unlike normal healing, the inflammatory process in fibrosing mediastinitis does not stop, causing this dense tissue to compress or "choke" these vital structures. This can lead to severe complications, including superior vena cava syndrome (blockage of the main vein returning blood to the heart), narrowing of the pulmonary arteries, or airway obstruction.

What causes Fibrosing Mediastinitis?

The pathophysiology of fibrosing mediastinitis is generally linked to an exaggerated, fibrotic immune reaction. While the exact trigger can sometimes remain unknown (idiopathic), the most common known cause is a prior infection with Histoplasma capsulatum, a fungus found in soil. In some individuals, the body’s immune system continues to react to the presence of these fungal antigens long after the initial infection has cleared, resulting in the relentless deposition of fibrous, collagen-rich tissue.

Who is typically affected by Fibrosing Mediastinitis?

Fibrosing mediastinitis is considered a very rare disease. Because it is often misdiagnosed or under-reported, exact global prevalence numbers are difficult to establish, though it is most frequently identified in regions where histoplasmosis is endemic, such as the Ohio and Mississippi River Valleys in the United States. It can affect individuals of any age, though it is often diagnosed in young to middle-aged adults. Research indicates there is no significant gender bias, and it is not considered a hereditary or genetic condition.

Key characteristics and classifications

Clinicians generally categorize fibrosing mediastinitis based on the pattern of tissue growth:

• Focal form: The fibrous mass is localized, often causing compression of a specific vessel or airway.


• Diffuse form: The scarring is widespread throughout the mediastinum, often making the condition more challenging to treat surgically.


• Differential diagnosis: It is distinct from other mediastinal tumors because it is an inflammatory process rather than a malignant neoplasm (cancer).

Currently, 93 people with fibrosing mediastinitis have joined the DiseaseMaps.org community, sharing their unique diagnostic journeys and experiences with treatments like antifungals, immunosuppressants, or surgical stenting.

Next steps

• Consult a pulmonologist or a thoracic surgeon who specializes in mediastinal disorders.


• Request advanced imaging, such as a contrast-enhanced CT scan or MRI, to evaluate the extent of the fibrosis.


• Connect with the community at DiseaseMaps.org to find peer support and shared experiences.


• Discuss with your medical team whether your case is related to prior fungal exposure, as this may influence treatment options.

Disclaimer: This content is for informational purposes only and does not constitute professional medical advice, diagnosis, or treatment; always seek the advice of your physician or other qualified health provider with any questions regarding a medical condition.

References

• NIH Genetic and Rare Diseases Information Center (GARD): Fibrosing mediastinitis overview.


• Orphanet: Rare disease database entry for fibrosing mediastinitis.


• PubMed/NCBI: Clinical reviews on the management of chronic fibrosing mediastinitis.


• American Thoracic Society: Clinical guidelines on mediastinal inflammatory disorders.